incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Despite this lack of coverage, the law allows so called "greenfield agreements", where employers make an agreement in new workplaces to last up to 4 years (or 8 years for construction projects) without any strike action possible. For instance, in Shop, Distributive & Allied Employees Association v ALDI Foods Pty Ltd, the supermarket chain Aldi made an agreement with 17 prospective employees, ignoring the union, and the High Court said that under section 172 an agreement could be made even though the employees had not begun work. The FWC can make "scope orders" under section 238 on whether employee groups are fairly chosen, given geographical, operational or organisational distinction.
== Story == Medea is centered on Medea's calculated desire for revenge against her unfaithful husband. Medea is of divine descent and has the gift of prophecy. She married Jason and used her magic powers and advice to help him find and retrieve the golden fleece. The play is set in Corinth some time after Jason's quest for the Golden Fleece, where he met Medea. The play begins with Medea in a blind rage towards Jason for arranging to marry Glauce, the daughter of king Creon. The nurse, overhearing Medea's grief, fears what she might do to herself or her children. Creon, in anticipation of Medea's wrath, arrives and reveals his plans to send her into exile. Crouching at Creon's feet, Medea begs him in the name of her children to allow her one day's delay. At this Creon is moved and grants to her one more day in Corinth. Medea's unexpected power of persuasion or even of fascination lies in her change of attitude: instead of preaching to Creon about the unpopularity of the sophoi she plays the role of a desperate mother, needing one day to prepare for exile. Medea is aware of the humiliating quality of this tactic, but she justifies it on the grounds of a gain and of her need to remain in Corinth: "Do you think that I would ever have flattered that man unless I had some gain to make or some device to execute? I wouldn't have even spoken or touched him with my hands". In the next scene Jason arrives to explain his rationale for his apparent betrayal.
Half-Life: Blue Shift is an expansion pack for the first-person shooter video game Half-Life (1998). It was developed by Gearbox Software and published by Sierra On-Line. Blue Shift was the second expansion for Half-Life, originally intended as part of a Dreamcast port of Half-Life. Although the Dreamcast port was cancelled, the Windows version was released as a standalone product on June 12, 2001. As with Gearbox's previous expansion pack, Opposing Force (1999), Blue Shift returns to the setting and events of Half-Life, but portrays the story through the eyes of another character. Players control security guard Barney Calhoun, employed by the Black Mesa Research Facility, who must fight his way to safety during an alien invasion. Blue Shift also includes a graphics pack that upgrades the Half-Life models and textures. Blue Shift received mixed reviews. Many reviewers were critical of the short length and lack of new content, although the new graphics were praised.
Sources: en.wikipedia.org
== Management == Katherine Stueland was appointed CEO of GeneDx in 2021. Under her leadership, the company refocused its operations on exome and genome sequencing for rare disease diagnosis. Stueland has been recognized for her work in genomic medicine, including being named to CNBC's Changemakers list in 2025 and to the TIME100 Health list in 2026. Kevin Feeley was appointed CFO in 2022. Prior to joining GeneDx, Feeley served as CFO of BioReference Laboratories and held senior roles at KPMG LLP. Bryan Dechairo was appointed COO in 2025.
== Sources and bioavailability == Naringenin and its glycoside has been found in a variety of herbs and fruits, including grapefruit, oranges, and lemons, sour orange, sour cherries, tomatoes, cocoa, Greek oregano, water mint, as well as in beans. Ratios of naringenin to naringin vary among sources, as do enantiomeric ratios. The naringenin-7-glucoside form seems less bioavailable than the aglycol form. Grapefruit juice can provide much higher plasma concentrations of naringenin than orange juice. Naringenin can be absorbed from cooked tomato paste. There are 3.8 mg of naringenin in 150 grams of tomato paste.
=== Combinations === Many cancer patients do not respond to immune checkpoint blockade. Response rate may be improved by combining that with additional therapies, including those that stimulate T cell infiltration. For example, targeted therapies such as radiotherapy, vasculature targeting agents, and immunogenic chemotherapy can improve immune checkpoint blockade response in animal models. Combining immunotherapies such as PD1 and CTLA4 inhibitors can create to durable responses. Combinatorial ablation and immunotherapy enhances the immunostimulating response and has synergistic effects for metastatic cancer treatment. Combining checkpoint immunotherapies with pharmaceutical agents has the potential to improve response, and as of 2018 were a target of clinical investigation. Immunostimulatory drugs such as CSF-1R inhibitors and TLR agonists have been effective. Two independent 2024 clinical trials reported that combinations of JAK inhibitors with anti–PD-1 immunotherapy could improve efficacy. A phase 2 trial investigated the combination as a first-line therapy for metastatic non-small-cell lung cancer. Administration of itacitinib after treatment with pembrolizumab improved therapeutic response. A separate phase 1/2 trial with patients with relapsed/refractory Hodgkin's lymphoma combined ruxolitinib and nivolumab, yielding improved clinical efficacy in patients who had previously failed checkpoint blockade immunotherapy.
Sources: en.wikipedia.org
The combat of Trails is turn-based with tactical elements. Unlike most other turn-based games, the series lacks random encounters as most enemies are visible on the overworld. Combat takes place on a large grid, with characters only able to move across a set number of squares or perform a single ability each turn. Turns are listed on a timeline on the screen, which can be manipulated with certain abilities. In addition to basic attacks and item usage, every character has abilities known as Crafts and Arts. Crafts are unique to each character and are usually unlocked or strengthened by leveling up. S-Crafts are a character's ultimate ability fueled by a meter that builds as they deal and take damage. When full, players can use it at any time to bypass the turn order to perform skills such as dealing large amounts of damage or supporting their party with healing and buffs. Arts are magic-like spells that are powerful but take time to cast. Rather than being unique to any specific character or monster like Crafts, Arts are determined by the type and specific arrangement of Quartz, items similar to Materia from Final Fantasy VII. Each successive game usually introduces new gameplay mechanics, such as the addition of Persona-like social events in Trails of Cold Steel or the optional action-based combat system in Trails Through Daybreak.
Marine carbon is further separated into particulate and dissolved phases. These pools are operationally defined by physical separation – dissolved carbon passes through a 0.2 μm filter, and particulate carbon does not. There are two main types of inorganic carbon that are found in the oceans:
Parasitoid use of viruses: parasitoid wasps lay their eggs inside host caterpillars; to keep the caterpillar's immune system from killing the egg, a virus is also "laid" with the eggs. Two unrelated wasps use this trick. Short-lived breeders: species that are in the juvenile phase for most of their lives. The adult lives are so short most do not have working mouth parts. Unrelated species: cicada, mayflies, some flies, dragonfly, silk moths, and some other moths. Katydids and frogs both make loud sounds with a sound-producing organs to attract females for mating. Camouflage of two kinds: twig-like camouflage independently in walking sticks and the larvae of some butterflies and moths; leaf camouflage is found independently in some praying mantises and winged moths. Dipteran flies and Strepsiptera insects independently came up with whirling drumsticks halteres that are used like gyroscopes in flight. Carcinisation: a crustacean evolves into a crab-like form from a non-crab-like form. The term was introduced into evolutionary biology by L. A. Borradaile, who described it as "one of the many attempts of Nature to evolve a crab".
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.